As per reports, Zensar Technologies is to acquire a 100 percent membership interest in three-year-old US-based BridgeView Life Sciences, through its wholly owned subsidiary Zensar Technologies Inc, USA, for a total consideration of $25 million.

Under the terms, Zensar will pay $14 million as an upfront contract payment, subject to working capital, debt, and cash adjustments, and an additional $11 million by December 31, 2027, contingent on achieving performance and employment retention criteria.

Under the terms of the agreement, Zensar will make upfront payments totaling $14 million, subject to working capital, debt, and cash adjustments, and an additional $11 million by December 31, 2027, subject to achievement of performance and employment retention criteria.

“This strategic move strengthens Zensar's Healthcare and Life Sciences (HLS) vertical and expands its pharma commercial and product launch expertise. The acquisition positions Zensar to offer a more comprehensive suite of solutions to pharmaceutical, biotechnology, and medical device companies,” according to the company.

Pune-based Zensar Technologies, part of the $4.8 billion conglomerate RPG Group, had total services revenue of $591.3 million in FY24, with the U.S. accounting for 67.2 percent of the revenue share The HLS business share in FY24 fell to 9.6 percent from 10 percent in FY23 The HLS segment declined 6.4 percent in the fourth quarter ended March 31, 2012.

“BridgeView Life Sciences brings a team of seasoned professionals with deep life sciences knowledge and a successful track record. This aligns perfectly with our vision to be a leader in the HLS space. BridgeView's expertise in biopharma cloud CRM, information management, analytics, and program management combined with their established client base will significantly enhance our HLS offerings and accelerate our go‐to‐market strategy,” said Manish Tandon, CEO and managing director of Zensar Technologies.